Posts tagged with ‘Anders Rabbe’

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    asdfasdfsdaf asdfasdf asdasdf

    by
  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of…

    by
  • Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the…

    by
  • New Chairman and extended board at Isofol Medical AB (publ)

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday…

    by
  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in Chicago in June, Redeye brings…

    by
  • Isofol to present at the 10th Annual Biotech Showcase Conference

    Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief Commercial Officer Sven…

    by
  • Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

    Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)…

    by